Fibrocell Reports Phase II azficel-T Trial for Treatment of Vocal Cord Scarring Did Not Meet Primary Endpoints

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/29/2026

1. V
2. KLAC
3. F
4. STX
5. PYPL
6. BE
7. SWKS
8. CSGP
9. VRNS
10. NXPI

Go back to Fibrocell Reports Phase II azficel-T Trial for Treatment of Vocal Cord Scarring Did Not Meet Primary Endpoints

Wedbush Remains Sidelined on Fibrocell Science (FCSC) Following Azficel-T Program Failure

June 9, 2016 8:47 AM EDT

Wedbush maintained a Neutral rating on Fibrocell Science (NASDAQ: FCSC), and cut the price target to $1.50 (from $4.00), as the company reports failure of the azficel-T program. FCSC reported that azficel-T missed the primary endpoints assessing change from baseline at four months in mucosal wave... More

Roth Affirms Fibrocell Science (FCSC) at 'Buy' Following Azficel-T Phase 2 Miss in Vocal Cord Scarring

June 8, 2016 11:59 AM EDT

Roth Capital affirms Fibrocell Science, Inc. (Nasdaq: FCSC) at Buy with a price target of $5 after the company announced that primary endpoints were not... More